Eli Lilly to Acquire Seattle-Area Biotech in $1.5 Billion Bet on Next-Generation Shingles Vaccine

Eli Lilly to acquire Seattle-area biotech in $1.5 billion bet on next-generation shingles vaccine

Eli Lilly agreed to acquire Bothell, Wash.-based Curevo Vaccine for up to $1.5 billion in cash. The deal centers on a next-generation shingles vaccine that reduced side effects by more than half in a Phase 2 study.

Eli Lilly to acquire Bothell’s Curevo Vaccine for $1.5 billion

Pharmaceutical giant Eli Lilly plans to buy a biotechnology company in Bothell for $1.5 billion. Read more...

Eli Lilly to Acquire Bothell Vaccine Company Curevo to Advance Shingles Prevention

Bothell-based Curevo Vaccine, a privately held clinical-stage biotechnology company dedicated to developing vaccines with improved tolerability, has agreed to be acquired by Indianapolis-based Eli Lilly and Co. for $1.5 billion.

AAHI’s SLA-SE Adjuvant Technology Powers Lilly’s Acquisition of Curevo’s Next-Generation Shingles Vaccine

Open the article to view the coverage from City AM